FAYUVI Eligibility Turns on Preserved Function in MPS IIIA

The label defines a clinically narrower population

The FDA approved rebisufligene etisparvovec-hopf (FAYUVI) for neurologic manifestations of mucopolysaccharidosis type IIIA in a pediatric population with preserved neurodevelopmental function. The practical change is important: confirming MPS IIIA establishes the diagnosis, but it does not by itself establish that a child fits the labeled treatment population.

MPS IIIA, also called Sanfilippo syndrome type A, is an autosomal recessive lysosomal storage disorder caused by deficient N-sulfoglucosamine sulfohydrolase activity. Accumulation of heparan sulfate particularly affects the central nervous system. Children may initially acquire skills, then show slowing development, behavioral changes, sleep disturbance and progressive cognitive and adaptive decline. The timing and pace vary, so chronological age cannot reliably substitute for functional assessment.

For treatment selection, the relevant population has three linked features: pediatric age, a confirmed MPS IIIA diagnosis and enough retained neurodevelopmental function to satisfy the FDA label. “Preserved” should not be interpreted as normal development. A child may have measurable delay and still retain meaningful developmental capacity. Conversely, molecular confirmation and young age do not establish preservation when substantial regression has already occurred.

The approved indication concerns neurologic manifestations. It should not be broadened into a claim that the therapy reverses every somatic manifestation of MPS IIIA or restores skills already lost. Those conclusions would require evidence beyond the indication itself.

Why baseline function now carries regulatory weight

Rebisufligene etisparvovec was studied as a one-time gene therapy intended to deliver a functional SGSH gene. The registered development program included an open-label, single-group phase 1/2 study rather than a randomized comparison with placebo or standard care. That design is understandable in an ultra-rare, progressive pediatric disorder, but it makes baseline characterization and comparison with the expected natural history especially consequential.

Without randomization, observed developmental trajectories can be influenced by age at treatment, disease severity, genotype, measurement variability and differences between treated participants and external natural-history cohorts. Biomarker changes can demonstrate biological activity, but they do not automatically establish the magnitude or durability of clinical benefit. The FDA’s regulatory conclusion and the complete prescribing information therefore remain the controlling sources for the approved population and conditions of use.

Preserved neurodevelopmental function matters biologically because gene replacement is intended to alter subsequent disease progression; it cannot be assumed to reconstruct neuronal networks after advanced degeneration. It also matters methodologically. Developmental assessments become harder to interpret near the lower limits of an instrument, while severe behavioral, sensory or motor impairment may obscure the abilities being measured.

The available regulatory and registry sources do not support a randomized effect estimate against an untreated concurrent control. Accordingly, no causal effect size, confidence interval or comparative p-value should be inferred from the approval alone. Clinicians and policymakers should distinguish the FDA’s benefit-risk determination from evidence that would have arisen from a conventional, adequately powered randomized trial.

Documentation becomes an immediate selection issue

A referral packet should make the diagnostic and functional evidence reviewable. Confirmation of MPS IIIA ordinarily rests on compatible biochemical findings, deficient SGSH enzyme activity and biallelic pathogenic or likely pathogenic variants in SGSH, interpreted in the appropriate clinical context. Documentation should also establish the child’s current neurologic and developmental status rather than relying only on an assessment performed months or years earlier.

A useful baseline record includes the name and version of the developmental instrument, testing date, chronological age, age-equivalent and standardized results when available, domain-level findings, raw scores and the examiner’s interpretation. Reporting only a composite score may conceal an uneven profile. Language, cognition, motor function, adaptive behavior, attention and social participation can diverge substantially in MPS IIIA.

Longitudinal records add context. Prior evaluations, school or early-intervention reports and caregiver observations can show whether skills are being acquired slowly, plateauing or being lost. They do not replace standardized assessment, but they help distinguish a single low score from a sustained trajectory. Testing conditions also matter: hearing or vision impairment, fatigue, sleep disruption, hyperactivity, acute illness and limited cooperation may depress apparent performance.

The label’s wording should govern eligibility. Clinicians should not create an unofficial cutoff, substitute chronological age for function or equate “preserved” with “asymptomatic.” If the prescribing information specifies an age range, assessment method or functional threshold, that language takes precedence over local shorthand. Borderline or internally inconsistent results warrant clarification by clinicians experienced in developmental testing and lysosomal disorders, not retrospective score selection.

This emphasis also affects referral pathways. Because MPS IIIA is progressive, waiting until unmistakable regression may move a child away from the population in whom retained function can be documented. That supports prompt evaluation after diagnosis. It does not support bypassing confirmatory testing, minimizing procedural risk or treating children outside the label as though evidence were equivalent.

Important uncertainties remain

The central limitation is the evidence design. An open-label, single-group study is vulnerable to selection bias, expectancy effects, informative missing data and imperfect external comparators. Small samples in an ultra-rare disease limit precision and make subgroup conclusions uncertain. Children enrolled in a gene-therapy study may also differ from the broader MPS IIIA population in age, disease stage, geography and access to specialist assessment.

Long-term durability remains a separate question from initial approval. Developmental trajectories must be interpreted over years, and delayed adverse events are particularly relevant after gene therapy. Post-treatment follow-up and any FDA-required postmarketing studies will be important for establishing whether biomarker effects translate into sustained functional benefit and for characterizing uncommon harms.

Generalizability is also constrained by the preserved-function requirement itself. Results in children treated before advanced decline should not be extrapolated automatically to those with extensive regression. Evidence is likewise insufficient to assume benefit for other MPS III subtypes, which involve different enzymatic defects.

For health systems, equitable access to valid developmental assessment is now part of implementing the indication. Children who lack prior testing, English-language proficiency or access to experienced neuropsychology services should not be misclassified because their records are sparse. The answer is better assessment and interpretation, not lowering evidentiary standards or treating absence of documentation as proof of preserved function.

Questions clinicians ask

Does a confirmed MPS IIIA diagnosis make a child eligible?

No. Diagnostic confirmation establishes the disorder, while the labeled population also requires pediatric status and preserved neurodevelopmental function. The complete FDA prescribing information should be checked for any additional age, testing or clinical criteria before treatment is considered.

Does preserved function mean development must be normal for age?

Not necessarily. Preserved function can coexist with developmental delay; the key issue is whether meaningful neurodevelopmental capacity remains under the label’s criteria. A current standardized assessment, longitudinal history and documentation of factors that could distort testing provide a more defensible determination than age or caregiver impression alone.

What should be documented before referral?

Records should include biochemical and molecular confirmation, a recent developmental evaluation with instrument and domain-level results, evidence of the child’s trajectory, and relevant neurologic, sensory and behavioral findings. This documentation supports label-based review but does not replace the treatment center’s eligibility and safety assessment.

Can the approval be extrapolated to advanced disease or other MPS III types?

The evidence does not support automatic extrapolation. Children with advanced neurodevelopmental loss fall outside the preserved-function population described by the approval, and other MPS III subtypes result from different enzyme deficiencies. Any use beyond the labeled population would carry greater uncertainty about benefit and risk.

References

1. FDA Approves FAYUVI for Neurologic Manifestations of MPS IIIA — U.S. Food and Drug Administration, 2026 2. Study of ABO-102 in Patients With Mucopolysaccharidosis Type IIIA — ClinicalTrials.gov, n.d. 3. Mucopolysaccharidosis Type III — GeneReviews, National Center for Biotechnology Information, n.d.